This collaboration with Bayer provides external validation for OP-3136 and expands its potential into prostate cancer, a large market. The upcoming ASCO data readout on May 30, 2026, for the Phase 1 monotherapy study is a key near-term catalyst. Monitor for initial safety and efficacy data from the Phase 1 study, which will inform the probability of success for the broader OP-3136 program.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $13.55entry
- T+1 · 6mo ago −4.72%α −4.74% · $12.91
- T+5 · 6mo ago −6.20%α −7.28% · $12.71
- T+20 · 5mo ago −15.42%α −13.48% · $11.46
- T+60 · 3mo ago −16.53%α −19.26% · $11.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT6 inhibitor, OP-3136, in combination with Bayer's NUBEQA (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer (mCRPC). The study is expected to initiate in H2 2026, with Bayer supplying darolutamide and Olema leading the study. Olema retains full global commercial and marketing rights to OP-3136. This is the first clinical collaboration for OP-3136, providing validation and potential expansion into a new indication beyond breast cancer.
Key Facts
- Olema entered a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 (KAT6 inhibitor) in combination with NUBEQA (darolutamide) in mCRPC.
- Phase 1b/2 study will enroll approximately 36 patients with mCRPC; expected to initiate in H2 2026.
- Bayer will supply darolutamide; Olema will lead the study and retain full global commercial and marketing rights to OP-3136.
- This is the first clinical collaboration for OP-3136, which is currently in a Phase 1 monotherapy study and being evaluated in combination with fulvestrant and palazestrant in ER+/HER2- metastatic breast cancer.
- Initial clinical data from the Phase 1 study of OP-3136 will be presented at ASCO on May 30, 2026.
Financial Impact
No financial terms disclosed; Bayer supplies drug, Olema retains full commercial rights to OP-3136.
Risk Factors
- Phase 1b/2 study is early-stage and may not demonstrate sufficient efficacy or safety.
- No financial terms disclosed; the collaboration does not provide immediate funding or milestone payments.
- OP-3136 is still in early clinical development; the ASCO data may be mixed or underwhelming.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-237832 |
| Document: olma-ex99_1.htm | 0001193125-26-237832 |
| Document: 0001193125-26-237832-index-headers.html | 0001193125-26-237832 |
| Document: 0001193125-26-237832-index.html | 0001193125-26-237832 |
| Document: 0001193125-26-237832.txt | 0001193125-26-237832 |
Track record
20 reports on OLMA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers